Last checked at 
Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Says trading in line with expectations with revenue for the six months ended December 31 at GBP54.0 million, up 6.9% from GBP50.5 million the year prior.
Adds results of a trial for general allergy treatment ImmunoBon, which will launch in Germany in January, show a significant improvement compared to baseline while maintaining an "excellent" safety and tolerability profile.
Also says Steve Smith will step down from his role of non-executive director in November after 17 years with the company.
Current stock price: 20.60 pence
Year-to-date change: up 24%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
